Basilea Pharmaceutica - Need for innovation against severe infections
At its recent capital markets day (CMD) and with the support of key opinion leaders, Basilea highlighted the rising need for innovative therapies...
189 Views
Basilea Pharmaceutica - CARB-X grant for preclinical programs
In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from...
306 Views
Basilea Pharmaceutica - Zevtera crosses key US regulatory hurdle
Basilea has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe bacterial infections (three...
340 Views
Basilea Pharmaceutica - Strong Cresemba traction triggers milestone payment
Continued strong sales of Cresemba, Basilea Pharmaceutica’s lead antifungal asset, in the Asia-Pacific region and China, has triggered the receipt...
234 Views
Basilea Pharmaceutica - From strength to strength
FY23 was another strong year for Basilea, marked by successive guidance beats and meaningful progress in fortifying its product pipeline. Revenues...
180 Views